ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma

被引：9
|
作者：
Gardner, Heather L. [1 ]
Harrington, Bonnie K. [1 ]
Izumi, Raquel [2 ]
Hamdy, Ahmed [2 ]
Kaptein, Allard [3 ]
Van Lith, Bart [3 ]
London, Cheryl A. [1 ]
Byrd, John C. [4 ]
Johnson, Amy J. [4 ]
Kisseberth, William C. [1 ]
机构：
[1] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA
[2] Acerta Pharma, San Carlos, CA USA
[3] Acerta Pharma, Oss, Netherlands
[4] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1744
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1744
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
    Jingjing Wu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 9
  • [2] Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
    Wu, Jingjing
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [3] Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
    Harrington, Bonnie K.
    Gardner, Heather L.
    Izumi, Raquel
    Hamdy, Ahmed
    Rothbaum, Wayne
    Coombes, Kevin R.
    Covey, Todd
    Kaptein, Allard
    Gulrajani, Michael
    Van Lith, Bart
    Krejsa, Cecile
    Coss, Christopher C.
    Russell, Duncan S.
    Zhang, Xiaoli
    Urie, Bridget K.
    London, Cheryl A.
    Byrd, John C.
    Johnson, Amy J.
    Kisseberth, William C.
    PLOS ONE, 2016, 11 (07):
  • [4] ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity
    Harrington, Bonnie K.
    Gulrajani, Michael
    Covey, Todd
    Kaptein, Allard
    Van Lith, Bart
    Izumi, Raquel
    Hamdy, Ahmed
    Ulrich, Roger Glenn
    Byrd, John C.
    Lannutti, Brian J.
    Johnson, Amy J.
    BLOOD, 2015, 126 (23)
  • [5] The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia
    Herman, Sarah E. M.
    Montraveta, Arnau
    Niemann, Carsten U.
    Mora-Jensen, Helena
    Gulrajani, Michael
    Krantz, Fanny
    Harrington, Bonnie K.
    Covey, Todd
    Lannutti, Brian J.
    Izumi, Raquel
    Ulrich, Roger G.
    Byrd, John C.
    Wiestner, Adrian
    Johnson, Amy J.
    Woyach, Jennifer A.
    BLOOD, 2015, 126 (23)
  • [6] Telomerase activity in B-cell non-Hodgkin lymphoma
    Ely, SA
    Chadburn, A
    Dayton, CM
    Cesarman, E
    Knowles, DM
    CANCER, 2000, 89 (02) : 445 - 452
  • [7] The novel BTK and P13K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models
    Gaudio, E.
    Tarantellii, C.
    Spriano, F.
    Bernasconi, E.
    Targa, A.
    Dirnhofer, S.
    Stathis, A.
    Zucca, E.
    Bertoni, F.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S39 - S40
  • [8] Radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Witzig, Thomas E.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 655 - 668
  • [9] Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma
    Lima Ribeiro, Marcelo
    Reyes-Garau, Diana
    Vinyoles, Meritxell
    Profitos Peleja, Nuria
    Carvalho Santos, Juliana
    Armengol, Marc
    Fernandez-Serrano, Miranda
    Sedo Mor, Alicia
    Bech-Serra, Joan J.
    Blecua, Pedro
    Musulen, Eva
    De La Torre, Carolina
    Miskin, Hari
    Esteller, Manel
    Bosch, Francesc
    Menendez, Pablo
    Normant, Emmanuel
    Roue, Gael
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6591 - 6601
  • [10] Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
    Postema, EJ
    Boerman, OC
    Oyen, WJG
    Raemaekers, JMM
    Corstens, FHM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (11) : 1725 - 1735
12345